CA2381056A1 - Hsv-1 recombinant et vaccins viraux actifs - Google Patents

Hsv-1 recombinant et vaccins viraux actifs Download PDF

Info

Publication number
CA2381056A1
CA2381056A1 CA 2381056 CA2381056A CA2381056A1 CA 2381056 A1 CA2381056 A1 CA 2381056A1 CA 2381056 CA2381056 CA 2381056 CA 2381056 A CA2381056 A CA 2381056A CA 2381056 A1 CA2381056 A1 CA 2381056A1
Authority
CA
Canada
Prior art keywords
hsv
gene
virus
dna
glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2381056
Other languages
English (en)
Inventor
Yechiel Becker
Yael Asher
Sergey Bujanover
Tamir Ben-Hur
Gholamreza Darai
Roland Kehm
Michal Moyal
Angela Rosen-Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2381056A1 publication Critical patent/CA2381056A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un herpès simplex virus recombinant dont le génome a été altéré par des mutations ou des délétions dans les gènes uniques de petite taille 8 et 12. L'invention concerne également des vaccins comprenant ledit herpès simplex virus recombinant.
CA 2381056 1999-08-03 2000-08-03 Hsv-1 recombinant et vaccins viraux actifs Abandoned CA2381056A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL131212 1999-08-03
IL13121299A IL131212A0 (en) 1999-08-03 1999-08-03 Recombinant virus and live-virus vaccines
PCT/IL2000/000469 WO2001009361A1 (fr) 1999-08-03 2000-08-03 Hsv-1 recombinant et vaccins viraux actifs

Publications (1)

Publication Number Publication Date
CA2381056A1 true CA2381056A1 (fr) 2001-02-08

Family

ID=11073099

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2381056 Abandoned CA2381056A1 (fr) 1999-08-03 2000-08-03 Hsv-1 recombinant et vaccins viraux actifs

Country Status (6)

Country Link
EP (1) EP1210448A1 (fr)
JP (1) JP2003505103A (fr)
AU (1) AU6313000A (fr)
CA (1) CA2381056A1 (fr)
IL (1) IL131212A0 (fr)
WO (1) WO2001009361A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150110822A1 (en) * 2011-09-08 2015-04-23 Benevir Biopharm, Inc. Oncolytic herpes simplex virus and therapeutic uses thereof
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063835B2 (en) 2000-01-21 2006-06-20 Biovex Limited Virus strains
JP2004532849A (ja) * 2001-04-20 2004-10-28 カイロン コーポレイション 中枢神経系へのポリヌクレオチド薬剤の送達
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US7592169B2 (en) 2003-04-25 2009-09-22 Medimmune, Llc Methods and compositions for treatment and prevention of HSV-2 infections and conditions
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
CA2663109A1 (fr) 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsylvania Vaccins contre le hsv-1 et le hsv-2 et methodes d'utilisation
CA2674051C (fr) 2006-12-28 2017-10-31 The Trustees Of The University Of Pennsylvania Vaccins combines de sous-unites du virus herpes simplex et methodes d'utilisation
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
CN102657861A (zh) * 2010-08-16 2012-09-12 郑州金森生物科技工程有限公司 单纯疱疹病毒ⅰ型基因重组减毒活疫苗及其制备方法
EP3937960A4 (fr) * 2019-03-14 2023-03-29 Research Institute at Nationwide Children's Hospital Mutants d'herpès simplex oncolytique syncytiaux en tant qu'agents thérapeutiques anticancéreux puissants
CN111635913B (zh) * 2020-06-16 2022-03-04 广东东阳光药业有限公司 构建体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150110822A1 (en) * 2011-09-08 2015-04-23 Benevir Biopharm, Inc. Oncolytic herpes simplex virus and therapeutic uses thereof
US9623059B2 (en) * 2011-09-08 2017-04-18 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
US10105404B2 (en) 2011-09-08 2018-10-23 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
US10456432B2 (en) 2011-09-08 2019-10-29 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
US11147846B2 (en) 2011-09-08 2021-10-19 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses

Also Published As

Publication number Publication date
IL131212A0 (en) 2001-01-28
AU6313000A (en) 2001-02-19
WO2001009361A1 (fr) 2001-02-08
EP1210448A1 (fr) 2002-06-05
JP2003505103A (ja) 2003-02-12

Similar Documents

Publication Publication Date Title
Pomeranz et al. Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine
US6541009B1 (en) Viral vaccines
Maes Felid herpesvirus type 1 infection in cats: a natural host model for alphaherpesvirus pathogenesis
Turin et al. BHV-1: new molecular approaches to control a common and widespread infection
Matsumura et al. An equine herpesvirus type 1 recombinant with a deletion in the gE and gI genes is avirulent in young horses
Da Costa et al. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease
Kimman et al. Inactivation of glycoprotein gE and thymidine kinase or the US3-encoded protein kinase synergistically decreases in vivo replication of pseudorabies virus and the induction of protective immunity
Mettenleiter et al. Role of glycoprotein gIII of pseudorabies virus in virulence
JPH10503372A (ja) Ｈｓｖウイルスベクター
JPH08507784A (ja) ウイルス・ワクチン
JP2006335763A (ja) 遺伝子、腫瘍及びウイルス感染の治療、並びにプログラムされた細胞死（アポトーシス）を予防するための方法及び組成物
Spector et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs
Aurelian et al. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10)
CA2381056A1 (fr) Hsv-1 recombinant et vaccins viraux actifs
Abendroth et al. Varicella‐zoster virus immune evasion
Sussman et al. A feline herpesvirus-1 recombinant with a deletion in the genes for glycoproteins gI and gE is effective as a vaccine for feline rhinotracheitis
JP4044131B2 (ja) ヘルペスウイルスワクチン
WO2007049409A1 (fr) Hsv recombinant utile pour le traitement d'un gliome humain
US20100291142A1 (en) Bacterial Artificial Chromosome Containing Feline Herpes Virus Type 1 Genome and Uses Thereof
Kinchington Latency of varicella zoster virus; a persistently perplexing state
US20040185056A1 (en) Vaccines containing bovine herpesvirus 1 attenuated by mutation in latency-related gene
ES2324406T3 (es) Mutantes de herpesvirus equino (ehv) gm-negativos sin elementos heterologos.
Holman et al. Neurovirulent factor ICP34. 5 uniquely expressed in the herpes simplex virus type 1 Δγ 1 34.5 mutant 1716
Goodman et al. Identification, transfer, and characterization of cloned herpes simplex virus invasiveness regions
Ahn et al. Properties of an equine herpesvirus 1 mutant devoid of the internal inverted repeat sequence of the genomic short region

Legal Events

Date Code Title Description
FZDE Discontinued